[Thromboembolic disease in pediatric oncology]
A Theron1, C Biron-Andreani2, S Haouy3
1Département d'onco-hématologie pédiatrique, CHU de Montpellier, 371, avenue du Doyen-Gaston-Giraud, 34090 Montpellier, France; Département d'hématologie biologie, centre régional de traitement de l'hémophilie, CHU de Montpellier, 80, avenue Augustin-Fliche, 34090 Montpellier, France.
Summary
Childhood cancer survival is improving, but treatment complications like thromboembolic venous disease remain a challenge. This article outlines strategies for preventing and treating this common cancer complication in children.
Area of Science:
- Pediatric Oncology
- Hematology
- Vascular Medicine
Background:
- Childhood cancer survival rates approach 80% due to advancements in diagnostics and treatment.
- Treatment-associated complications, particularly thromboembolic venous disease, present a significant challenge.
- Thromboembolic venous disease affects up to 40% of children with cancer, causing considerable morbidity.
Purpose of the Study:
- To address the challenge of thromboembolic venous disease in pediatric cancer patients.
- To propose a concise decision tree for the prevention and treatment of thromboembolic venous disease.
- To guide clinical practice in managing this frequent complication.
Main Methods:
- Review of current literature on pediatric thromboembolic venous disease.
- Analysis of risk factors, including genetic and environmental predispositions.
- Development of a decision-making algorithm for prophylaxis and treatment.
Main Results:
- Thromboembolic venous disease is common in pediatric cancers like leukemia, lymphoma, and sarcoma.
- Primary prophylaxis is indicated for specific high-risk pediatric populations.
- Low-molecular-weight heparin is the established curative treatment.
Conclusions:
- Effective management of thromboembolic venous disease is crucial for improving outcomes in childhood cancer.
- A structured approach, including prophylaxis and timely treatment, is essential.
- Further pediatric-specific prospective studies are needed to refine strategies.
More Related Videos
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
281
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
281
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
334
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
334
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
256
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
256
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
318
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
318
01:30Inflammatory Bowel Disease II: Crohn's Disease
1.2K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.2K
01:25Immunodeficiency Diseases
2.5K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
2.5K